Moneycontrol
HomeNewsBusinessWork from home: Infosys looking at hybrid workplace model for the future

Work from home: Infosys looking at hybrid workplace model for the future

Infosys' decision is in sharp contrast to TCS’ work from home decision.

June 27, 2020 / 21:05 IST
Story continues below Advertisement

Infosys is looking at a hybrid model, where some portion of the employees will work from home (WFH) and office in the coming months, said UB Pravin Rao, COO, Infosys.

Speaking at the 39th Infosys Annual General Meeting, Rao said, “What we are looking at is a model, where some of our employees will continue to work from home and others from office.”

Story continues below Advertisement

“But it is too early to say how many will work from office in the future,” he added.

This comes at the back of the shift IT industry witnessed due to the pandemic. Since March, IT firms enabled WFH for thousands of its employees in a matter of couple of weeks.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show